Comparison 2. Weekly versus daily azithromycin.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Relative change in FEV1 (% predicted)	1	624	Mean Difference (IV, Fixed, 95% CI)	‐0.77 [‐0.90, ‐0.65]
1.1 at 1 month	1	208	Mean Difference (IV, Fixed, 95% CI)	‐0.40 [‐0.60, ‐0.20]
1.2 at 3 months	1	208	Mean Difference (IV, Fixed, 95% CI)	‐1.20 [‐1.40, 1.00]
1.3 at 6 months	1	208	Mean Difference (IV, Fixed, 95% CI)	‐0.70 [‐0.95, ‐0.45]
2 Days to first pulmonary exacerbation	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2.1 After 6 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Adverse events	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Gastrointestinal	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Abnormal liver transaminases	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.3 Total adverse events	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.4 Study withdrawal	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Days in hospital	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 after 6 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Number of hospital admissions	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 After 6 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Acquisition of azithromycin‐resistant Staphylococcal aureus	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6.1 After 6 months	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Change in CRP	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
7.1 at 1 month	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 at 3 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.3 at 6 months	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]